Mr Mark Bishop

2021

• Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)

2005

• Sansom, O. J., Bishop, S. M., Bird, A. and Clarke, A. R. 2005. MBD2 deficiency does not accelerate p53 mediated lymphomagenesis. Oncogene 24(14), pp. 2430-2432. (10.1038/sj.onc.1208166)

2004

• Sansom, O. J., Bishop, S. M., Bird, A. and Clarke, A. R. 2004. MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR. Oncogene 23(33), pp. 5693-5696. (10.1038/sj.onc.1207767)

2003

• Sansom, O. J., Bishop, S. M., Court, H., Dudley, S., Liskay, R. M. and Clarke, A. R. 2003. Apoptosis and mutation in the murine small intestine: loss of MIh1- and Pms2-dependent apoptosis leads to increased mutation in vivo. DNA Repair 2(9), pp. 1029-1039. (10.1016/S1568-7864(03)00111-3)
• Sansom, O. J., Zabkiewicz, J., Bishop, S. M., Guy, J., Bird, A. and Clarke, A. R. 2003. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 22(46), pp. 7130-7136. (10.1038/sj.onc.1206850)
• Sansom, O. J., Berger, J., Bishop, S. M., Hendrich, B., Bird, A. and Clarke, A. R. 2003. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nature Genetics 34(2), pp. 145-147. (10.1038/ng1155)

2002

• Millar, C. B. et al. 2002. Enhanced CpG Mutability and Tumorigenesis in MBD4-Deficient Mice. Science, pp. 403-405. (10.1126/science.1073354)